

## Index to Volume 7

### Author Index

- Aboagye-Atta, Y., S233, S332  
Acar, J. F., S513, S545  
Acres, S. E., S191  
Adkinson, N. F., Jr., S613  
Agadzi, V. K., S233, S295, S332  
Aguirre Errasti, C., 700  
AhLoy, R. D., S506  
Albiez, E. J., 789  
Alexander, D. P., 284  
Allan, J. D., S559  
Andiman, W. A., S80  
Antal, G. M., S220  
Antúnez de Mayolo, E., S463  
Appell, M. W., S17  
Arguello, E. A., S458  
Ariza, J., 656  
Armstrong, D., 646  
Assaad, F., S28  
Azad, M. A. K., 244  
Aziz, M. A., 847, S528  
Baker, C. J., 458  
Balaya, S., S64  
Banatvala, J. E., S86  
Barboza, E., S463  
Barrett-Connor, E., 207  
Barriere, S. L., 284  
Barry, A. L., S594  
Bart, K. J., S22, S95, S177  
Bart, S. W., S95  
Bassford, P. J., Jr., S314  
Beaubien, M. S., S217  
Beeson, P. B., S65, S74  
Bella-Cueto, F., 635  
Belshe, R. B., 511  
Berger, R., S91  
Berger, S. A., 357  
Berman, S., 674  
Bernstein, S., S690  
Best, J. M., S86  
Biolini, D., S724  
Bitar, R., 257  
Blanco, J. D., S690  
Bland, J. A., S435  
Blumer, J. L., S482  
Bodey, G. P., 314, S741  
Bonner, D. P., S579  
Boom, W. H., 189  
Bouza, E., 143  
Bow, E. J., S747  
Brabin, B. J., 579  
Brannon, E. S., S65  
Brodeur, J. P., S635  
Brown, A. E., 613  
Brown, K. R., 847, S528  
Brown, R. B., 625  
Brown, S. T., S318  
Brunham, R. C., 665  
Buimovici-Klein, E., S113  
Burke, J. P., 560  
Burkhardt, F., S91  
Burman, L. A., 133  
Buser, F., S77  
Butler, T., 244  
Byrd, F. I., S150  
Calandra, G. B., 847, S435, S528  
Carberry, W. L., 200  
Casagran-Borrell, A., 635  
Casalino, E., S463  
Catterall, R. D., S343  
Causse, G., S220  
Chambers, S., 547  
Cheevers, W. P., 83  
Chiodini, P. L., S490  
Chow, A. W., 287  
Chubb, H., S747  
Clements, J. E., 68  
Cone, C. O., S675  
Cone, L. A., S794  
Conlon, C. P., S490  
Conly, J. M., S747  
Connor, D. H., 809  
Conte, J. E., Jr., 284  
Cooper, L. Z., S2, S123, S170  
Cork, L. C., 89  
Corral Carranceja, J., 700  
Cox, C. E., S767  
Csonka, G., S260  
Cynamon, M., S476  
Daffner, R. H., 10  
Daikos, G. K., S831  
Darougar, S., 726  
Davies, J. W., S191  
Dawson, C. R., 768  
DeGregorio, M. W., 619  
del Castillo, M., S463  
Demetriades, J. L., S435  
Deshmukh, D. R., 31  
Diaz-Mitoma, F., S452  
DiNubile, M. J., 232  
Dobersen, M. J., S170  
Dodson, M. G., S696  
Donnelly, J. J., 820  
Dorsett, P. H., S150, S157  
Drasin, G. F., 10  
Dreslinski, G. R., S648  
Dudgeon, J. A., 278, S86, S185  
Dunn, F. L., 783  
Dunning, S. B., 200  
Ebbesen, P., 708  
El Khalifa, M., 831  
Elting, L., 314, S741  
Emmons, J. E., S80  
Enders, G., 710, S103, S113  
Epstein, I., S42  
Espadaler, L., 656  
Espejo-Arenas, E., 635  
Evans, A. S., 434  
Evans, B. K., S80  
Fainstein, V., 314, S741  
Faro, S., S696  
Farrell, I. D., S490  
Fedun, B., S170  
Ferber, F., S435  
Fernandez-Nogues, F., 656  
Fernandez-Viladrich, P., 656  
Fihn, S. D., 468  
File, T. M., S476  
Finegold, S. M., S417  
Foege, W. H., S335  
Fong, I. W., 604  
Font-Creus, B., 635  
Foresman, P. A., S635  
Forlenza, S., 171  
Forsgren, M., S129  
Franson, T. R., 1  
Frasch, C. E., 504  
Furesz, J., S191  
Gal, P., 643  
Gambertoglio, J. G., 284  
García de la Torre, M., 143  
Gardner, M. B., 99  
Gavan, T. J., S594  
Gbakima, A. A., 789  
Geddes, A. M., S353, S490  
Genco, R. J., 387  
George, G. H., 809  
Georgsson, G., 75  
Gerckens, L., S389  
Gibbs, R. S., S690  
Gibson, D. W., 809  
Gilles, H. M., 111  
Gillissen, J., S825  
Ginsberg-Fellner, F., S170  
Goldmann, D. A., S482  
Gong, Y., S79  
Gonzalez del Riego, M., S463  
Gorse, G. J., 511  
Gould, A. L., 613  
Gratz, J. C., S715  
Grayston, J. T., 717  
Green, K. Y., S150  
Greene, B. M., 789  
Gross, P. A., 613  
Grundy, B. J., S157  
Gudiol, F., 656  
Gudnadóttir, M., S200  
Guerra, J. G., S463  
Guerra de Macedo, C., S217

- Guerrero, A., 143  
 Haidar Abu Ahmed, M., S239  
 Hall, H. J., S666  
 Hamilton, R. G., 837  
 Han, Y., S79  
 Handwerker, S., 368  
 Hansen, C., 643  
 Hansen, R. S., S506  
 Hao, S., S79  
 Hara, K., S810  
 Harding, G. K. M., S452, S747  
 Hardy, P. H., S300  
 Harris, R. L., 119, 314  
 Hartstein, A. I., S482  
 Henry, S., S703, S729, S789  
 Hermann, K. L., S95, S108  
 Hermans, P. E., 498  
 Hewlett, E. L., 426  
 Hierholzer, W. J., Jr., 1  
 Hinman, A. R., S22, S95, S177, S212  
 Hinthorn, D. R., S476  
 Hirayama, M., S56  
 Holleran, W. M., 619  
 Hollows, F. C., 777  
 Hopfer, R. L., 314, S25  
 Hopkins, D. R., S233, S332, S338  
 Horn, R., 646  
 Hornick, R. B., S36  
 Hornstein, L., S42  
 Horstmann, D. M., S80  
 Huapaya, V., S463  
 Hudson, J. R., S37  
 Hume, J. C., S343  
 Hunter, E. F., S295  
 Iglewski, B. N., S482  
 James, M., S452, S747  
 Janssens, P. G., S289  
 Jasovich, A., S458  
 Jenkins, S. A., S772  
 Jewesson, P. J., 287  
 Johnson, A. P., 741  
 Johnson, J. D., 10  
 Johnson, R. J., 200  
 Johnson, R. T., 66  
 Jones, P., S741  
 Jones, R. N., S594  
 Jong, E. C., 200  
 Jukes, T. H., 702  
 Just, M., S91  
 Just, V., S91  
 Kääriäinen, L., S140  
 Kager, L., S432, S518  
 Kahan, F. M., S389  
 Kalkkinen, N., S140  
 Kallio, A., S140  
 Kasper, D. L., 458  
 Kass, E. H., S762  
 Katz, J. R., S506  
 Kaye, D., S476, S656  
 Kiehn, T. E., 646  
 Klustersky, J., S552  
 Klein, R. J., 21  
 Klemm, P., 321  
 Knight, J., 244  
 Knowlton, D. R., S157  
 Knox, E. G., S194  
 Kobayashi, H., S810  
 Kofi, F., S295  
 Kono, R., S56  
 Krilov, L. R., S482  
 Kron, M. A., 625  
 Kropp, H., S389  
 Krugman, S., S1  
 Kubens, B., S426  
 Kunitomo, D., 665  
 Kunin, C. M., 547  
 Kuo, C., 717  
 Kwon-Chung, K. J., 272  
 LaBrecque, D. R., 1  
 Larsen, S. A., S295  
 Larson, D. L., S25  
 Ledger, W. J., S679  
 Lee, T. J., S783  
 Lee, W. H. S., 272  
 Levison, M. E., S476, S656  
 Levy, S. B., 560  
 Lewis, J. O., S295  
 Libertin, C. R., 498  
 Lin, J.-S. L., 216  
 Liska, S., S295  
 Liu, C., S476  
 Ljungar-Esteves, K., S28  
 Lo, E. K. C., S251  
 Louie, T. J., S452, S747  
 Lovett, M. A., S295  
 Lukehart, S. A., S305  
 Lutley, R., 75  
 McCabe, R. E., S496  
 McCue, J. D., 643  
 MacDonald, A. B., 731  
 McEvoy, R. C., S170  
 McGowan, J. E., Jr., S357  
 McGuire, T. C., 83  
 McIntosh, K., 674  
 McKellar, P. P., S803  
 Mackenzie, C. D., 802, 831  
 Maglio, F., S458  
 Manjunath, N., S64  
 Margaret, M. A., S37  
 Martínez-Beltrán, J., 143  
 Martone, W. J., 479  
 Mayer, K. H., S371  
 Meheus, A., S284  
 Meisinger, M. A. P., S435  
 Melbye, M., 708  
 Menser, M. A., S37  
 Mercade-Cuesta, J., 635  
 Meseguer, M., 143  
 Meyer, R. D., S506  
 Miller, D. C., S150  
 Milton, A., S47  
 Mingle, J. A. A., S68  
 Minshaw, B. H., 200  
 Miyamura, K., S56  
 Moellering, R. C., Jr., S559  
 Montejó Baranda, M., 700  
 Moraes, M. F., S724  
 Morens, D. M., 479  
 Muir, J. G., S675, S772  
 Muñoz-Espin, T., 635  
 Murphy, A. M., S37  
 Najjar, J. A., 75  
 Narayan, O., 89  
 Nath, S. K., 244  
 Nathanson, N., 75  
 N'Da, K., S237  
 Nelson, J. W., S233, S295, S332  
 Neu, H., S537, S669, S778, S840  
 Newman, T. J., S648  
 Nichols, R. L., S709  
 Nielsen, D. M., S506  
 Niemel, P. L. A., S273  
 Nishiura, T., S810  
 Noah, N., S47  
 Nolen, T. M., S666  
 Nolla-Salas, M., 635  
 Nord, C. E., S432, S518  
 Norrby, S. R., 133, S447, S836  
 Notkins, A. L., S170  
 O'Day, J., 802  
 Ofori, J. A. K., S295  
 Oker-Blom, C., S140  
 Onorato, I. M., 479  
 Opferkuch, W., S426  
 Orenstein, W. A., S22, S95, S177  
 Ores, C. N., S669  
 O'Shea, S., S86  
 Ottesen, E. A., 341, 796  
 Pace, J., S260  
 Pallares, R., 656  
 Palomino, J. C., S463  
 Pálsson, P. A., 75  
 Partanen, P., S140  
 Patton, D. L., 746  
 Peckham, C., S11  
 Perine, P. L., S233, S295, S332  
 Perkins, F. T., S73  
 Pettersson, R. F., S140  
 Pétursson, G., 75  
 Phillips, H. L., S666  
 Philipson, A., S432  
 Plotkin, S. A., S77  
 Plotzner, R., S476  
 Poolman, J. T., 504  
 Preblud, S. R., S22, S95, S177  
 Prince, A. S., S669  
 Pruett, T. L., 151  
 Raff, M. J., 10  
 Ramia, S., 180  
 Randolph, M. F., S80  
 Rayner, E., S747  
 Reid, D., S47  
 Reid, M. S., S254

- Remington, J. S., S496  
 Rockey, J. H., 820  
 Rodeheaver, G. T., S635  
 Rogers, J. D., S435  
 Rolston, K. V. I., S25, S741  
 Romero-Vivas, J., 143  
 Ronald, A. R., S452  
 Rotstein, O. D., 151  
 Roy, S. K., 244  
 Rubinstein, P., S170  
 Ruff, G., 656  
 Sadal, S., S273  
 St. John, R. K., S266  
 Saito, A., S810  
 Sands, M., 625  
 Sattler, F. R., S622  
 Saxon, A., S613  
 Schachter, J., 713, 754, 768  
 Schatzmayr, H. G., S53  
 Scheld, W. M., S635  
 Schentag, J. J., S716  
 Schiff, G. M., S157  
 Schilt, U., S91  
 Schimpff, S. C., S734  
 Schluederberg, A., S80  
 Schmid, G. P., 41  
 Schoenbaum, S. C., S210  
 Schramm, M., S622  
 Schweiker, R. S., S218  
 Scully, B. E., S669, S789  
 Segura-Porta, F., 635  
 Seth, P., S64  
 Sever, J. L., S164  
 Shafer, W. M., 398  
 Shaver, K. A., S164  
 Shah, P. M., S471  
 Sheppard, S., S47  
 Shibl, A. M., 51  
 Simmons, R. L., 151  
 Simons, G. W., S716  
 Simons, W. J., S783  
 Sisley, B. M., 802, 831  
 Smith, E. G., S490  
 Smith, I. L., S716  
 Smithells, R. W., S47  
 Snow, J., 441  
 Snyderman, R., 387, 390  
 Soares de Souza, O., S724  
 Sommer, A., 765  
 Soulsby, E. J. L., 820  
 South, M. A., S164  
 Speelman, P., 244  
 Spence, M. R., S613  
 Spitznagel, J. K., 398  
 Stagg, R. J., 284  
 Stambouliau, D., S458  
 Stamler, E. F., S157  
 Stamm, L. V., S314  
 Stamm, W. E., 468  
 Stansfield, S. K., 479  
 Stapleton, J. T., S314  
 Stefanovic, G. M., S157  
 Stern, R. C., S482  
 Stetler, H. C., S95  
 Stevens, D. P., 530  
 Steward, M. W., 802  
 Stierstedt, G., S432  
 Stille, W., S353, S825  
 Su, W., S72  
 Sugishita, C., S56  
 Sundelof, J. G., S389  
 Swabb, E. A., S605, S613, S622, S675, S772  
 Swanson, D. J., S716  
 Swartz, T. A., S42  
 Sweet, R. L., S522  
 Sykes, R. B., S579  
 Tadros, S. S., S648  
 Tam, M. R., S295  
 Tan, J. S., S476  
 Tarpley, J., 257  
 Taub, F., S170  
 Taylor, H. R., 711, 737, 765, 789, 820, 844  
 Thompson, J. E., Jr., 171  
 Thomson, M., S452  
 Thornberry, C., S594  
 Thylefors, B., 774  
 Tobin, J. O'H., S47  
 Tomasz, A., 368  
 Tomkins, K. B., 604  
 Touré, I. M., S242  
 Treharne, J. D., 760  
 Trollfors, B., 133  
 Trumbore, D., S476  
 Tuazon, C., 189  
 Ulmanen, I., S140  
 Upfold, L. J., S37  
 Uribe, W. R., S276  
 Vaheri, A., S140  
 Valverde, J. M., 656  
 van der Sluis, J. J., S273  
 van der Waaij, D., S628  
 Van Dyke, T. E., 419  
 Varughese, P., S191  
 Verma, R., 171  
 Vidal-Sanahuja, R., 635  
 Vigano, A., S716  
 Villar, O., S458  
 Vorst, F. A., S327  
 Vosti, K. L., S496  
 Wang, Changtai, S79  
 Wang, Cynthia, 847, S528  
 Wang, San-pin, 717  
 Wang, Shuzhen, S79  
 Warren, J. V., 565  
 Washington, J. A., II, 498  
 Waxham, M. N., S133  
 Weimer, C. W. C., S426  
 Weinstein, L., 692, S538  
 Weiss, N., 826  
 Wels, P. B., S716  
 Werk, R., 449  
 Wexler, H. M., S417  
 Widy-Wirski, S227  
 Wilbur, J. R., 619  
 Willcox, R. R., S278  
 Williams, D. M., 754  
 Williams, J. D., S411  
 Williams, J. F., 802, 831,  
 Williams, N. M., S95  
 Williams, T. W., Jr., 119  
 Wilson, J., S198  
 Wilson, M. E., 387, 404  
 Winslade, N. E., S716  
 Witt, M. E., S170  
 Wolinsky, J. S., S133  
 Wong, B., 646  
 Woodard, D. R., S794  
 Wright, S. D., 395  
 Yeh, L., 717  
 Yoo, D., 272  
 Young, B. C., S157  
 Young, L. S., S380, S572  
 Yura, J., S810  
 Zahra, A., S245  
 Zhao, K., S79  
 Zinner, S. H., S371  
 Zollinger, W. D., 504

## Subject Index

- Abscess, splenic, 10
- Abdominal sepsis. *See* Intraabdominal sepsis
- Abortion, treatment of infection in, S679
- Adherence, bacterial, effect of antibiotics on and clinical implications of, 51
- Adhesins, fimbrial, of *E. coli*, 321
- Aeromonas*, bacteremia due to in cancer patients, 314
- Africa, tropical, seroepidemiology of rubella in, S68
- AIDS-like epidemic, recommendations for future handling (letter), 708
- Amebic liver abscess, treatment of, 171
- Aminoglycosides, for noninfectious diseases, 357
- Amphotericin B, with or without flucytosine for candida infection, 646
- Anaerobic bacteria, in vitro susceptibility to imipenem, S417
- Anaerobic infections, in obstetrics and gynecology, treatment of, S679
- Anaerobic-aerobic infections, pelvic, treatment with imipenem/cilastatin, S522
- Ancylostoma duodenale*, in hookworm infection, 111
- Anemia
  - Equine infectious, 83
  - due to hookworm infection, 111
- Animal models
  - of bacteremia, 151
  - of human disease due to nononcogenic retroviruses, 66
- Antagonism, between  $\beta$ -lactam antibiotics, S559
- Antibiotic(s) (*see also names of individual agents*; Antimicrobial agents)
  - and adherence of microorganisms to epithelial cells, 51
  - charges for in hospitals, 643
  - growth effect, 702
  - resistance
    - economic issues related to, 560
    - mechanisms of, S545
    - in treponemes, potential for development in, S314
    - worldwide surveillance of, 560
  - tolerance to, among clinical bacterial isolates, 368
  - usage, 547
    - economic issues related to, 560
    - in hospitals, 547
    - IDSA members and fellows views on, 547
    - policies on, locally, nationally, and internationally, 560
    - worldwide, 560
- Antifungal agents, for noninfectious diseases, 357
- Antimicrobial agents (*see also* Antibiotic(s))
  - in animal feed, 547
  - combinations, in therapy for gram-negative bacillary infection, S559
  - for noninfectious diseases, 357
  - pharmacokinetics and safety during pregnancy, 287
- Aureomycin (chlortetracycline), discovery and effects of, 702
- Aztreonam
  - for aerobic bacterial infections, directed therapy for, symposium on, S537-843
  - allergy to, S605
  - animal studies of, S579
  - antibacterial activity of, S579
  - for bacteremia due to gram-negative aerobic bacteria, S789
  - $\beta$ -lactamase inhibition by, S634
  - $\beta$ -lactamase stability of, S579, S594
  - clinical experience with
    - in Europe, S836
    - in Germany and Austria, S825
    - in Japan, S810
    - in the Mediterranean, S831
  - clinical pharmacology of, S605
  - incombinations, S579
  - cross-allergenicity to penicillins and cephalosporins, S613
  - in cystic fibrosis patients with respiratory tract infections due to *P. aeruginosa*, S679
  - disk-diffusion susceptibility tests for, determinations and quality control, S594
  - for experimental brain abscess, cerebritis, and meningitis, S635
  - for gram-negative aerobic bacterial infections (*see* Gram-negative bacterial infections)
  - immunogenicity of, S613
  - in intraabdominal infections, S729
  - extravascular penetration of, S716
  - vs. tobramycin, S724
  - mode of action, S579
  - for neutropenic patients with febrile episodes, S741, S747
  - for obstetric-gynecologic infections, S703
  - for osteomyelitis due to gram-negative bacilli, including *P. aeruginosa*, S783
  - overview and summary of symposium, S840
  - pharmacokinetics of in abdominal sepsis, S716
  - in renal insufficiency, safety of and serum concentrations in, S622
  - for respiratory tract infections, S675
  - resistance incidence, S594
  - safety of in clinical trials, S622, S648
  - selective decontamination of the digestive tract with, S628
  - for septic arthritis due to gram-negative bacilli, S783
  - for serious gram-negative aerobic bacterial infections, S794, S803, S810, S825, S831, S836
  - symposium on, S537-S843
  - vs. tobramycin
    - for intraabdominal infections, S724
    - for lower respiratory tract infections due to gram-negative bacilli, S666
  - for urinary tract infections due to gram-negative aerobic bacteria, S767, S772
  - worldwide clinical trials, S675, S772
  - in vitro activity, S594
- Bacteremia
  - due to *Aeromonas*, in hospitalized cancer patients, 314
  - animal models of, 151
  - due to gram-negative aerobic bacteria, treatment with aztreonam, S789
  - due to gram-negative aerobic bacilli, S559
  - hyperbilirubinemia, association with, 1
  - nosocomial, changing etiology of, S357
  - due to *Streptococcus* group F, 498
- Bacterial
  - endocarditis. *See* Endocarditis, bacterial
  - infections (*see also names of specific infections*)

- chemotherapeutic requirements for, S380
- serious, treatment with imipenem/cilastatin, S490, S496, S506
- pathogens, hospital-acquired, S371
- synergy, 151
- Bacteroides fragilis*, activity of imipenem against in vitro, S411
- Bacteriuria, in the elderly and excess mortality due to, S762
- Bejel. *See* Treponematoses, nonvenereal
- Benefit-cost analysis, of rubella immunization, S210
  - $\beta$ -lactam antibiotics
  - allergy to, S605
  - antagonism between, S559
  - tolerance of by clinical bacterial isolates, 368
- Blindness, infectious causes of (*see under* Onchocerciasis; Trachoma)
- Bordetella pertussis*, strategies for control of disease due to, 426
- Borrelia burgdorferi*, as etiologic agent of Lyme disease, 41
- Boutonneuse fever, 635
- Brain abscess
  - due to *P. boydii* associated with non-Hodgkin's lymphoma of CSF, case report, 272
  - treatment with antibiotics alone, 189
  - treatment of multiple, 189
- Brazil, rubella infection in, S53
- Bronchiolitis, etiology and management in the developing world, 674
- Brucella melitensis*, spondylitis caused by, 656
- Brucellosis, manifested as spondylitis, 656
- Brugia malayi*, treatment of filariasis due to with diethylcarbamazine, 341
- Brugia timori*, treatment of filariasis due to with diethylcarbamazine, 341
- Candidiasis, in patients with cancer, 646
- Caprine arthritis, 68 (*see also* Lentivirus)
- Caprine arthritis-encephalitis virus, 89
- Cefotaxime, compared with imipenem/cilastatin for treatment of severe bacterial infections, S452, S458
- Ceftazidime, for meningitis due to *P. aeruginosa*, 604
- Cell-mediated immune response
  - in chlamydial infection, 754
  - in onchocercal infection, 789
  - in rubella infection, S123
- Cephalosporins, third-generation, resistance to, S559
- Cesarean section, endometritis following, role of gram-negative bacilli in, S690
- Chemotaxis, mechanisms of in polymorphonuclear leukocytes, 390
- China, People's Republic of
  - rubella in, S72
  - rubella vaccine in, S79
- Chlamydia psittaci*, original description of infection due to, 119
- Chlamydia trachomatis* (*see also* Trachoma)
  - antibodies to, diagnostic tests for detection, 726
  - antigens of, role in infection, immunity, and immunopathology, 731
  - blindness due to, prevention of, 713
  - cell-mediated immunity in infections due to, 754
  - and *C. psittaci*, differentiation of antigens, 731
  - effect of infection on immune response, 665
  - epidemiology of disease due to, use of risk-factor studies, 765
  - experimental eye infections and immunization in monkeys, 717
  - genital tract infection due to, pathogenesis and immunology of, 741
  - immunization with in monkeys, 717
  - overview of infection due to, 713
  - salpingitis, experimental, in pig-tailed macaques, 746
  - summary of workshop on infection due to, 711
  - vaccine, requirements for, 713
- Chlamydial infection
  - animal models of, 737
  - humoral immune response in and detection of, 726
  - in obstetrics and gynecology, antibiotic treatment of, S679
  - ocular immunity to, 754
- Chloramphenicol
  - for intestinal perforation in typhoid fever, 257
  - for noninfectious diseases, 357
- Chlortetracycline
  - discovery and effects of, 702
  - effect on farm animals, 702
- Cholera, errors made in epidemiology by Austin Flint (1843), 434
- Chronic disease
  - due to lentivirus infection, 89
  - due to nononcogenic retroviruses, 66
  - visna in sheep, 75
- Cilastatin
  - as inhibitor of renal metabolism of imipenem, S447
  - pharmacokinetics of, S435
- Colonization resistance, maintenance of during therapy with aztreonam in febrile neutropenic patients, S747
- Complement, regulation of receptors for C3, 395
- Congenital rubella infection and syndrome (*see under* Rubella)
- Corynebacterium diphtheriae*, strategies for control of disease due to, 426
- Costs, hospital, for antibiotics, 643
- Coxsackievirus B infection
  - as cause of insulin-dependent diabetes mellitus, 207
  - epidemiology and diagnosis of, 207
- Croup, etiology and management in the developing world, 674
- Cystic fibrosis, treatment of pulmonary exacerbations due to *P. aeruginosa* in, S482, S669
- Cytomegaloviral infection, epidemiology, prevention, and treatment of, 479
- Deafness, and congenital rubella infection, S11
- Demyelination, in visna virus infection in sheep, 75
- Developing countries (*see also under* Primary health care)
  - viral waterborne infections in, 180
- Diabetes mellitus, insulin-dependent
  - in congenital rubella syndrome, S170
  - epidemiology of, 207
  - relation to coxsackievirus B infection, 207
- Diethylcarbamazine (*see also under* Onchocerciasis)
  - in treatment of filariasis, 341
- Diphtheria, strategies for control in developing countries, 426
- Disablement prevention, and rubella control, S198
- Drechslera* species, human infections caused by, 525
- Elderly patients, safety of aztreonam in, S622
- Empiric therapy
  - with amphotericin B in patients with acute leukemia, 619
  - for neutropenic febrile patients, S734
- Endemic trepanematoses. *See* Trepanematoses, endemic



- Enders, J. F., presentation of Galen Medal to, 278
- Endocarditis, bacterial  
 classic paper on by P. B. Beeson et al., 565  
 commentary on early study of, 574  
 penicillin for treatment of, 565, 574  
 removal of bacteria from blood in, 565
- Endometritis, role of gram-negative aerobic bacilli in, S690
- Endomyometritis, postpartum, treatment of, S679
- Endotoxins, effects on neutrophil function, 387, 404
- Entamoeba histolytica*, liver abscess due to, 171
- Enteric viruses, waterborne transmission of, 180
- Enterobacteriaceae, serum resistance with imipenem, S426
- Epidemic diseases, classic paper on by J. Snow, 441
- Epidemiology (see also names of specific diseases)  
 of cytomegaloviral infection, 479  
 enteric, errors made in by Flint and von Pettendofer, 434  
 of infection in pregnancy, 579  
 of rubella. See Rubella
- Epithelial cell surfaces, effects of antibiotics on adherence to, 51
- Equine infectious anemia, immunity and viral persistence in, 83
- Errata  
 Barriere et al. (1984;6:S812), 284  
 Enders, G. (1985;7:S113), 710  
 Wang et al. (1985;7:S528), 847
- Escherichia coli*  
 fimbrial adhesins of, 321  
 role of in endometritis after cesarean section, S690
- Exanthematic fever, due to *R. conori*, 635
- Fever of unknown origin, benign, 692
- Fibronectin, enhancement of C3-mediated phagocytosis by, 395
- Filariasis (see also Onchocerciasis)  
 immunoassay methods in diagnosis of, 837  
 treatment with diethylcarbamazine, 341
- Fimbriae, of *E. coli*, 321
- Flint, Austin, errors made by in enteric epidemiology, 434
- N*-Formimidoyl thienamycin. See Imipenem
- Frambesia tropica. See Yaws
- Fungal infections  
 chemotherapeutic requirements for, S380  
 empiric amphotericin B for in acute leukemia, 619
- Fungemia  
 as nosocomial infection, S357  
 in patients with cancer, 646
- Galen Medal, presentation to J. F. Enders, 278
- Genital infection  
 due to *C. trachomatis*, 741  
 due to *M. tuberculosis*, in men, 511
- Gentamicin/clindamycin, compared with imipenem/cilastatin for treatment of infections in hospitalized patients, S463
- Giardia lamblia*, disease due to in developing world, 530
- Giardiasis, strategies for control in developing world, 530
- Gram-negative bacteria (see also under Gram-negative bacterial infections)  
 resistance and problems and changing patterns, S545
- Gram-negative bacterial infections  
 antimicrobial combinations in treatment of, S559  
 aztreonam treatment of  
 bacteremia, S789  
 endometritis, S690  
 Mediterranean experience, S831  
 Japanese experience, S810  
 pneumonia, S656  
 respiratory tract, compared with tobramycin, S666  
 serious infections, S794, S803, S810, S825, S831, S836  
 systemic, S794  
 directed therapy for aerobic (aztreonam), symposium on, S537-S843  
 nosocomial (bacillary), in compromised hosts, prevention and therapy, S552  
 overviews, S538, S572, S778  
 Granulocytes, transfusions with for therapy, 232
- Gynecologic infections. See Obstetric and gynecologic infections
- Haemophilis influenzae*, meningitis due to, treatment with aztreonam, S635
- Herpes simplex virus, initiation and maintenance of latent infections, 21
- Hookworm infection, due to *A. duodenale* and *N. americanus*, epidemiology, control, and treatment of, 111
- Hospital-acquired infection. See Nosocomial infection
- Host-cell invasion, by *Toxoplasma gondii*, 449
- Humoral immunity, in *O. volvulus* infection, 789
- Hyperbilirubinemia, frequency and characteristics associated with bacteremia, 1
- Imipenem (see also Imipenem/cilastatin)  
 anaerobic bacteria, susceptibility to, S417  
 antibacterial activity, review of worldwide experience, S389  
 pharmacokinetics of, S435  
 against *Pseudomonas* and *Bacteroides* species in vitro, S411  
 renal metabolism of, S447  
 and serum resistance in Enterobacteriaceae, S426  
 summary of symposium on, S353  
 symposium on, S353-S536
- Imipenem/cilastatin  
 clinical rationale for use of combination, S447  
 and colonic microflora, S432  
 compared with cefotaxime  
 for lung, soft tissue, and renal infections, S452  
 for severe bacterial infections, S458  
 compared with gentamicin/clindamycin for moderate-to-severe infections, S463  
 in cystic fibrosis patients for pulmonary exacerbations due to *P. aeruginosa*, S482  
 efficacy and safety, in worldwide experience, S528  
 experience with in a multicenter study, S471  
 for intraabdominal infections, worldwide experience, 518  
 for lower respiratory tract infections, worldwide experience, S513  
 for nosocomial infection, S371  
 for obstetric and gynecologic infections, worldwide experience, S522  
 pharmacokinetics of in volunteers, S435  
 for serious bacterial infections, S452, S458, S463, S476, S490, S496, S506
- Immune response  
 and *C. trachomatis* infection, 665  
 to influenza virus vaccine, effect of cancer chemotherapy on, 613
- Immunosuppressed patients  
 infection in, S538  
 nosocomial infection with gram-negative bacilli in, S552

- Immunization. *See name of specific disease or vaccine*
- India, seroepidemiology of rubella in, S64
- Influenza virus vaccine, effect of cancer chemotherapy on response to, 613
- Insulin-dependent diabetes mellitus. *See* Diabetes mellitus, insulin-dependent
- International Initiative Against Avoidable Disablement (U.N. program), S198
- Intestinal perforation, due to typhoid fever, 244, 257
- Intraabdominal infections
- animal models of, 151
  - bacteriology of, S709
  - comparison of aztreonam plus clindamycin vs. tobramycin plus clindamycin for treatment of, S724
  - overview of, S709
  - treatment with aztreonam, S716, S729
  - treatment with imipenem/cilastatin, S518
- Ixodes* species, in Lyme disease, 41
- Japan, epidemiology of rubella in, S56
- Klebsiella*, susceptibility patterns of bacteremia isolates in Spanish hospital, 143
- Klebsiella oxytoca*, bacteremia due to, 143
- Klebsiella pneumoniae*, bacteremia due to, 143
- Latent infections, due to herpes simplex virus, 21
- Latex agglutination test, for detection of antibodies to rubella, compared with HAI test, S80
- Lentiviruses (*see also* Retroviruses)
- caprine arthritis encephalitis virus, 68
  - and chronic disease, 68
  - in progressive inflammatory disease, 89
  - and pneumonitis, leukoencephalitis, and arthritis, 89
  - prototype infection with, 75
  - in visna of sheep, 75, 89
- Leukemia
- acute, amphotericin B therapy in patients with, 619
  - therapy for, with granulocyte transfusions, 232
- Leukocytes, polymorphonuclear
- activation of by chemoattractants, 390
  - regulation of chemoattractant receptors on, 390
- Leukoencephalitis, in goats, 89
- Liver abscess, due to *E. histolytica*, treatment with metronidazole, 171
- Localized juvenile periodontitis, role of neutrophil in, 419
- Lung fluke, infection with, treatment with praziquantel, 200
- Lyme disease, geographic occurrence of, 41
- Lymphoma, of CNS, non-Hodgkin's, brain abscess with *P. boydii* associated with, 272
- Macrophages, strategies in phagocytosis, 395
- Maedi, in sheep, 89
- Mazzotti reaction, to diethylcarbazine treatment, 787, 796, 802, 809
- Mediterranean spotted fever, 635
- Membrane proteins, of *N. meningitidis*, 504
- Meningitis
- due to gram-negative aerobic bacilli, treatment with aztreonam, S803
  - due to *H. influenzae*, treated with aztreonam, S635
  - due to *P. aeruginosa*, treatment with ceftazidime, 604
- Methodologic analysis, of urinary tract infection treatment trials, 468
- Metronidazole
- for amebic liver abscess, 171
  - for noninfectious diseases, 357
- Microflora
- colonic, effect of imipenem/cilastatin on, S432
  - indigenous, disease due to in immunosuppressed patients, S538
- Modelling, rubella vaccination strategies, S194
- Monobactams, properties of, relations to penicillins and cephalosporins, and structure-activity studies, S579
- Monoclonal antibodies
- rubella virus protein analysis using, S150
  - specific for rubella virus, S133
  - in studies of onchocerciasis, 826
- Mycobacterium tuberculosis*, male genital infections due to, 511
- Mycoplasma hominis*, in human genital infections, 216
- Mycoplasma pneumoniae*, in upper respiratory tract infections, 216
- Mycoplasmas, human infections due to, serologic observations in, 216
- Necator americanus*, hookworm due to, 111
- Neisseria meningitidis*
- outer membrane proteins of, 504
  - serotyping of, 504
- Neonatal infection, due to group B *Streptococcus*, 458
- Neutropenia
- empiric therapy for febrile patients with, S734
  - empiric therapy for cancer patients with, comparison of aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin, S741
  - infection associated with, S734
  - preservation of colonization resistance with aztreonam therapy in febrile patients with, S747
  - use of granulocyte transfusions for prevention and treatment of, 232
- Neutrophils. *See* Polymorphonuclear leukocytes
- Nosocomial infections
- bacterial, S371
  - changing etiology of, S357
  - due to cytomegalovirus, 479
  - due to gram-negative bacilli in compromised hosts, prevention and therapy, S552
  - due to *Klebsiella*, in a Spanish hospital, 143
  - pathogens of increasing significance in, S371
- Obstetric and gynecologic infections (*see also* Pelvic inflammatory disease)
- antibiotic treatment, problems in, S679
  - aztreonam therapy for, S703
  - imipenem/cilastatin therapy for mixed aerobic-anaerobic, S522
- Onchocerca lienalis*, experimental model of infection, ocular lesions in, 820
- Onchocerca volvulus* (*see also* Onchocerciasis)
- antigens of, immunodiagnostic and immunopathogenic, 831
  - host-response variations and pathogenesis of infection due to, 802, 809
  - humoral and cellular immune responses to in humans, 789
  - immunologic aspects of disease due to, review of, 787
  - ocular pathology in experimental models of infection with, 820

- Onchocercal dermatitis, and subcutaneous nodules in, 802, 809  
 Onchocercal lymphadenitis, sclerosing, 809  
 Onchocerciasis (*see also Onchocerca volvulus*)  
   control programs, vector control and chemotherapy aspects of, 844  
   diethylcarbamazine treatment, results of, 802, 809  
   global priorities in control of, 844  
   host responses, variations of, 802  
   humoral and cellular immune responses in, 789  
   IgE in eye and skin pathology of, 796  
   immediate hypersensitivity in immunopathogenesis of, 796  
   immunoassay methods in diagnosis of, 837  
   introduction to and summary of workshop on, 787  
   monoclonal antibodies as investigative tools in, 826  
   non-ocular manifestations of, 809  
   pathologic changes in, dermatitis, nodules, and lymphadenitis in, 802, 809  
   research requirements for, 802, 809  
   WHO programs for control of, 844  
   workshop on, 787-846  
 Osteomyelitis, due to gram-negative bacilli, treatment with aztreonam, S789  
 Pancreatic islet cell antibodies, in patients with congenital rubella syndrome, S170  
 Paragonimiasis, pulmonary, epidemiology, clinical presentation and treatment, 200  
 Pelvic inflammatory disease, acute, etiology, epidemiology, diagnosis, and treatment of, S696  
 Pentamidine, review of therapy with, 625  
 Periodontal disease, role of neutrophil in, 419  
 Persistent infection  
   by nononcogenic retroviruses, 89  
   with visna in sheep, 75  
 Pertussis, strategies for control in developing countries, 426  
 Phagocytic cells  
   collection of papers on, 387-425  
   effect of antibiotics on microbial adherence to, 51  
   oxygen-independent bactericidal properties of, 387  
   receptor modulation of, 387  
   summary of symposium on, 387  
 Phagocytosis, mediated by complement, 395  
 Pharmacology, clinical, of aztreonam, S605  
 Pharmaceutical industry, relation of IDSA to, 547  
 Pharmacokinetics  
   of antibiotics during pregnancy, 287  
   of aztreonam in abdominal sepsis, S716  
 Pharyngitis, etiology and management of in the developing world, 674  
 Pinta  
   control of, S220, S338, S343  
   diagnosis and treatment of, S343  
 Pneumococcal infections  
   incidence, predisposing factors, and prognosis of, 133  
   in Sweden, 133  
*Pneumocystis carinii*, effect of pentamidine in vitro and in vivo, 625  
 Pneumonia  
   etiology and management in the developing world, 674  
   due to gram-negative bacilli, an overview, S656  
 Pneumotrophus, original description by J. Ritter, 119  
 Polymicrobial infections, in surgery, 151  
 Polymorphonuclear leukocytes  
   abnormal, diseases in which found, 419  
   historical summary of oxygen-dependent mechanisms of killing, 398  
   killing of gram-negative bacteria by, 398  
   modification of bactericidal properties of by endotoxin, 404  
   and periodontal disease, 419  
 Polysaccharides, capsular, of group B *Streptococcus*, 458  
 Praziquantel, for treatment of paragonimiasis, 200  
 Pregnancy  
   cellular and immune responses during, 579  
   epidemiology of infection during, 579  
   pharmacokinetics and safety of antimicrobial agents during, 287  
   recurrent infections during, 579  
   vertical transmission of infection in, 579  
 Primary health care  
   in developing countries  
     and giardiasis, 530  
     and hookworm infection and anemia, 111  
     and pertussis and diphtheria, 426  
     and respiratory infections (acute), 674  
     and typhoid fever, 536  
   yaws control as related to, S284  
*Pseudallescheria boydii*, brain abscess due to in non-Hodgkin's lymphoma of CNS, 272  
*Pseudomonas aeruginosa*  
   activity of imipenem against in vitro, S411  
   bacteremia due to, treatment of with aztreonam, S803  
   epidemiology and treatment of infections due to, S572  
   meningitis due to, treatment with ceftazidime, 604  
   osteomyelitis due to, treatment with aztreonam, S783  
   pulmonary infection in cystic fibrosis, treatment with imipenem/cilastatin, S482  
 Psittacosis, original description by J. Ritter, 119  
 Q fever, acute, in Basque country, clinical manifestations and treatment, 700  
 Radiologic diagnosis, of splenic abscess, 10  
 Receptors  
   for C3, regulated behavior of, 395  
   chemoattractant, on leukocytes, regulation of, 390  
 Relapsing disease, due to nononcogenic retroviruses, 66  
 Renal insufficiency, safety of aztreonam in patients with, S622  
 Respiratory infections  
   acute, control in developing world, 674  
   in cystic fibrosis patients, treatment with aztreonam, S669  
   due to gram-negative aerobic bacteria, treatment with aztreonam, S666, S675, S810  
   imipenem/cilastatin treatment of, S513  
 Retroviruses, nononcogenic (*see also specific viruses*; Lenti-viruses)  
   and CNS demyelination, 89  
   equine infectious anemia virus, 83  
   introduction to collection of papers on infections due to, 66  
   as models for chronic and relapsing human disease, collection of papers on, 66-110  
   molecular basis of disease caused by and antigenic variation in, 68



- murine neurotropic, 99
- organ tropisms of, 89
- and pneumonitis, leukoencephalitis, and arthritis, 66
- structure and replication, 68
- Reye's syndrome, animal models of, 31
- Rickettsia conori*, disease due to, 635
- Risk factors, studies of in trachoma, 765
- Ritter, J., original description of psittacosis by, 119
- Rubella
  - acquired, S29
  - antibody detection
    - of IgM and IgG, S113
    - in early pregnancy, S113
    - serodiagnostic kits for, S108
    - serologic tests, combinations for, S113
    - standardization of techniques and reagents for, S129
    - tests, methods for, S108
  - antibody persistence
    - after Cendehill, HPV-77 DE-5, RA27/3, and To-336 vaccination, S86
    - comparison of HAI, neutralizing, latex-agglutination, and ELISA titers postvaccination, S80
    - and immunity, S157
    - of virus-specific responses after vaccination, S86
  - cell-mediated immune response in, S123
  - congenital infection, S11, S29 (see also under Rubella, congenital syndrome)
    - in Australia, S37
    - clinical manifestations of, S17
    - cost-effectiveness of different prevention strategies, S200
    - delayed manifestations of, S164
    - embryopathy risk associated with, S2
    - in England and Wales, S11
    - epidemiology of, S11
    - history and medical consequences of, S2
    - in Iceland, prevention of, S200
    - in India, serologic study of, S64
    - introduction to symposium on, S1
    - magnitude of the problem, S2
    - manifestations of, S2
    - methods of assessing impact of, S22
    - pathogenetic mechanisms, S2
    - summary of symposium on prevention of, S212
    - surveillance of children with, S11
    - symposium on prevention of, S1-S215
    - virology and immunology of, S2
  - congenital syndrome (see also Rubella, congenital infection)
    - autoimmunity in, S170
    - delayed manifestations of, S164
    - disablement by, prevention of, S198
    - diabetes mellitus in, S170
    - education of handicapped children with, S17
    - effects on family and community, S17
    - hearing impairment associated with, S11
    - late sequelae of, S164
    - methods of assessing impact, S22
    - multihandicapped, programs for, S17
    - prevention and control of, S29, S198
  - epidemiology and occurrence
    - in Australia, S37
    - in Brazil, S53
    - in Canada, S191
    - in Israel, S42
    - in the People's Republic of China, S72
    - in the United Kingdom, S47
  - historical background of, S29
  - immunity
    - comparison of vaccine-induced and naturally acquired, S80
    - long-term after vaccination, S91
  - immunization against. See Rubella, vaccination against
  - postnatal, S2
  - seroepidemiology of
    - in India, S64
    - in tropical Africa, S69
  - surveillance, S29, S185
  - vaccination against, S103, S177, S185
    - antibody titer distribution following, S103
    - in Australia, S37
    - benefit-cost analysis, S210
    - cell-mediated response following, S123
    - in Canada, S191
    - duration of immunity after, S91
    - in the Federal Republic of Germany, S103
    - fetal risk associated with use of Cendehill, HPV-77, and RA27/3, S95
    - in Israel, S42
    - in Japan, effects of on seroepidemiology, S56
    - long-term evaluation of recipients, S157
    - persistence of antibodies after, S77, S86
    - during pregnancy, outcome, S103
    - selective
      - in Australia, S37
      - effects of, S185
      - in Israel, S42
      - in the United Kingdom, S185
    - strategies, theoretical aspects of, S194
    - in the United Kingdom, S11, S47
    - universal, S170, S177
    - in the United States, S177
- vaccine(s), S191
  - comparison of HPV-77 DE-5 and RA27/3, S80
  - currently available, S73
  - history of RA27/3, S77
  - in the People's Republic of China, S79
  - WHO requirements for, S73
- vaccines
  - challenge studies in, S86, S157
  - long-term evaluation of, S157
  - persistence of immunity in, S157
- virus
  - antigenic characteristics of, S140
  - functional analysis of structural proteins, S150
  - gene expression of, S140
  - molecular biology of, S140
  - monoclonal antibodies specific for, S133
  - structure of proteins, S133, S140, S150
- Salmonella typhi*
  - disease due to in developing world, 536
  - intestinal perforation in infection due to, 244, 257
- Salpingitis, experimental chlamydial in pig-tailed macaques, 746
- Salpingo-oophoritis, treatment of, S679

- Selective decontamination, with aztreonam or temocillin, S628
- Septic arthritis, due to gram-negative bacilli, treatment with aztreonam, S783
- Septicemia, nosocomial, etiology of, S357
- Serum resistance, effect of imipenim on in Enterobacteriaceae, S426
- Slow infections, due to nononcogenic retroviruses, 66
- Slow viruses. See Lentiviruses; Retroviruses
- Snow, John, classic paper on epidemic disease, 441
- Soft tissue infections, animal models of, 151
- Sowda, as manifestation of *O. volvulus* infection, 802, 809
- Spleen, abscess, radiology in, 10
- Spondylitis, due to *Brucella melitensis*, 656
- Spongiform encephalopathy, and retroviruses, 99
- Streptococcus*, group B, prevention of disease due to, 458
- Streptococcus*, group F, bacteremia due to, 498
- Streptococcus pneumoniae*, invasive infections due to, incidence, predisposing factors, and diagnosis, 133
- Sulfonamides and sulfones, for noninfectious diseases, 357
- Superinfection. See Suprainfection
- Suprainfection  
   during aztreonam treatment, S836  
   as result of multiple antibiotic therapy, S538
- Surgical infections  
   microbial synergy in, 151  
   polymicrobial, S709
- Synergy  
   between  $\beta$ -lactam agents and aminoglycosidic aminocyclitols, S559  
   microbial, in surgical infections, 151
- Syphilis  
   diagnosis and treatment of, S343  
   endemic  
     control of, S338  
     mass campaigns for control of, S220  
     mutilating, S260  
     in Saudi Arabia, S260  
     and venereal syphilis compared, S260  
     in West African states, S242  
   antibiotic resistance in, potential for development, S314  
   nonvenereal, in Saudi Arabia, S260  
   prevention and control of, S343  
   serologic diagnosis, S300  
   in the Sudan, S237  
   vaccine development, prospects for, S305
- Temocillin, selective decontamination of the digestive tract with, S628
- Tetracyclines, for treatment of noninfectious diseases, 357
- Thienamycin antibiotics, antibacterial activity of, S389 (see also under Imipenem)
- Tick-borne disease, 635
- Lyme disease, 41
- Tobramycin, vs. aztreonam for treatment of intraabdominal infections, S724
- Tolerance, antibiotic, in clinical bacterial isolates, 368
- Toxoplasma gondii*, mechanism of host-cell invasion, 449
- Trachoma (see also under *Chlamydia trachomatis*)  
   animal models in immunologic studies of, 737  
   antibiotic treatment of, 768  
   blinding, strategies for treatment and control of, 760, 768
- community-based action for the control of, 777
- control strategies, development of national programs for, 774
- cost-effectiveness of topical or systemic antibiotics in the treatment and control of, 768
- cultural dislocation and, 777
- epidemiologic studies of, in Taiwan, 717
- epidemiology of, 711, 760
- hygiene practices as risk factor in, 765
- immunology of, 711, 713
- immunopathology of, 717
- pathogenesis of, importance of reinfection in, 717
- prevention of, 711, 768, 774, 777, 783
- protective immunity in animal models of, 737
- reinfection, importance in pathogenesis of, 717
- research and intervention in, 783
- risk-factor analysis in epidemiologic studies of, 765
- sociomedical contributions to research and intervention in, 783
- summary and introduction of workshop on, 711
- workshop on, 711-786
- Treponema pallidum*  
   antibiotic resistance in, potential for development, S314  
   detection of in yaws lesions by fluorescein-conjugated antibody staining, S295  
   diagnosis of infection, S300  
   specific antigen detection in, S300  
   vaccine development, prospects for, S305
- Treponema pertenue*  
   antibiotic resistance to, potential for development of, S314  
   disease due to, S289 (see also Treponematoses; Yaws)
- Treponematoses (see also Pinta; Syphilis; Yaws)  
   clinical diagnosis and changing manifestations of, S327  
   diagnosis and treatment of, S343  
   endemic  
     International Union Against the Venereal Diseases and Treponematoses, resolution about (Appendix), S343  
     mass treatment campaigns against, S220, S278  
     prevention and control of, S220, S338, S343  
     in Saudi Arabia, S260  
     in the Sudan, S239  
     vertical and integrated programs for control, use of, S338  
     in West Africa, S242  
     World Health Assembly, resolution about (Appendix), S343  
   nonvenereal (bejel)  
     public health programs for control of, S314  
     in Saudi Arabia, S260  
     therapy with penicillin and other regimens, S314, S318  
     treatment recommendations, S318  
   serologic diagnosis of, S300  
   vaccines against, prospects for development, S305
- Trypanosomes, effect of pentamidine on in vitro and in vivo, 625
- Tuberculosis, extrapulmonary, 511
- Typhoid fever  
   epidemiology, errors made in by Pettenkofer (1854), 434  
   intestinal perforation in, 244  
     historical review of treatment, 257  
     treatment with surgery and antimicrobial agents, 244, 257  
   strategies for control in developing world, 536  
   vaccines against, 536
- United Kingdom, rubella infection in, S47
- Ureaplasma urealyticum*, in human genital infections, 216

## Urinary tract infections

- analysis and review of treatment trials in women, 468
- aztreonam treatment of gram-negative bacterial, S767, S810
  - vs. cefamandole, S772
  - vs. gentamicin and tobramycin, S772
  - vs. amoxycillin, S772

Vaccination (*see also name of specific disease or infection*)

- in Ghana, against measles, tuberculosis, neonatal tetanus, and yellow fever, S332

## Vaccines

- chlamydial, requirements for, 713
- rubella (*see under* Rubella)
- streptococcal, group B, 458
- treponemal, prospects for, S305
- typhoid fever, 536

Viruses (*see also name of specific virus*)

- enteric, waterborne transmission in developing countries, 180
- importance in nosocomial infection, S357

Visna (*see also under* Lentivirus)

- in sheep, 68
  - as complication of maedi, 89
  - pathogenesis of experimental infection, 75

## Visna virus, replication of and immune response to in sheep, 75

Vitamin B<sub>12</sub>, and growth of animals, 702

## von Pettenkofer, Max, errors in enteric epidemiology made by, 434

## Water, treatment of for elimination of virus, 180

## Waterborne infections, viral, transmission of in developing countries, 180

## Whooping cough, strategies for control in developing countries, 426

*Wuchereria bancrofti*, treatment of filariasis due to with diethyl-carbamazine, 341

## Yaws

- in Africa, mass campaigns against in 1980s, S278
- in the Americas, surveillance of, S266

## antibiotic resistance in, potential for, S314

## attenuated, clinical diagnosis of, S327

## in the Caribbean, control programs in, S266

## in Colombia, S266, S276

## campaigns against, S276

control of, S338 (*see also name of specific country or region or type of program*)

## early efforts, S278

## role of primary health care, S284

## strategies and technologic innovations needed for, S289

## diagnosis and treatment, S343

## in Ghana, control program and results, S233, S295

## impact on other diseases, S332

## mass penicillin treatment in, S332

## in Ivory Coast, epidemiology of, S237

## in Malaysia, distribution, manifestations, and control of, S251

mass treatment for control of, S220 (*see also name of specific country*)

## inadequacy of, S289

## and other endemic trepanematoses, symposium on, S217-S351

## preface to, S218

## summary of, S343

## in Papua New Guinea

## extent of the problem and status of control programs, S254

## recent outbreaks, S254

## resurgent

## atypical pattern of, S289

## surveillance and control of in African region, S227

## serologic surveillance for active latent cases, S295

## in Southeast Asia, overview of and control programs in, S245

## in the Sudan, S239

## in Suriname, S266, S273

## early salvarsan and penicillin campaigns against, S273

## surveillance and control, new technologies for, S295

## treponemal antigen tests with finger-prick blood, S295

## vaccine development, prospects for, S305

## in West Africa, S242

## Yellow fever, in Ghana, epidemics and vaccination, S332



## **Reviews of Infectious Diseases**

*An Official Publication of the Infectious Diseases Society of America*

*Edward H. Kass, Editor*

*Neil R. Blacklow, Associate Editor*

*John R. David, Associate Editor*

*Sherwood L. Gorbach, Associate Editor*

*Alice S. Huang, Associate Editor*

*Dennis L. Kasper, Associate Editor*

*Jerome O. Klein, Associate Editor*

*Joan B. Daniels, Assistant Editor*

*Nancy Kurz Voynow, Managing Editor*

*Julie McCoy, Manuscript Editor*

*Sarah Acheson Stephens, Manuscript Editor*

*Steven Berman, Editorial Assistant*

*Sara Lea Bernhard, Staff Assistant*

### **EDITORIAL BOARD**

Robert Austrian, Philadelphia, Pa.

Michael M. Frank, Bethesda, Md.

Lawrence R. Freedman, Los Angeles, Calif.

D. Carleton Gajdusek, Bethesda, Md.

King K. Holmes, Seattle, Wash.

Harold J. Jennings, Ottawa, Canada

Richard T. Johnson, Baltimore, Md.

Samuel L. Katz, Durham, N.C.

Thomas C. Merigan, Jr., Stanford, Calif.

Kenneth S. Warren, New York, N.Y.

Frank E. Young, Rochester, N.Y.

### **INTERNATIONAL BOARD OF DIRECTORS**

Jacques F. Acar, Paris, France

Ralph van Furth, Leiden, The Netherlands

C. H. Huang, Beijing, China

Lars O. Kallings, Stockholm, Sweden

Jean Klustersky, Brussels, Belgium

P. Helena Mäkelä, Helsinki, Finland

Francis O'Grady, Nottingham, England

Theodore G. Sacks, Jerusalem, Israel

David A. J. Tyrrell, London, England

Yuichi Yamamura, Osaka, Japan

**Volume 7**

**January-December 1985**



All rights reserved  
THE UNIVERSITY OF CHICAGO PRESS, CHICAGO  
THE UNIVERSITY OF CHICAGO PRESS LTD., LONDON S.W. 1

---

© 1985 BY THE UNIVERSITY OF CHICAGO  
PUBLISHED BIMONTHLY JANUARY-DECEMBER

---

PRINTED IN USA

# Reviews of Infectious Diseases

Volume 7 • Number 1 • January-February 1985

## REVIEW ARTICLES

TIMOTHY R. FRANSON, WALTER J. HIERHOLZER, JR., AND DOUGLAS R. LABRECQUE	Frequency and Characteristics of Hyperbilirubinemia Associated with Bacteremia	1
JUDITH D. JOHNSON, MARTIN J. RAFF, GEORGE F. DRASIN, AND RICHARD H. DAFFNER	Radiology in the Diagnosis of Splenic Abscess	10
RICHARD J. KLEIN	Initiation and Maintenance of Latent Herpes Simplex Virus In- fections: The Paradox of Perpetual Immobility and Continuous Movement	21
DEVENDRA R. DESHMUKH	Animal Models of Reye's Syndrome	31
GEORGE P. SCHMID	The Global Distribution of Lyme Disease	41
ATEF M. SHIBL	Effect of Antibiotics on Adherence of Microorganisms to Epithelial Cell Surfaces	51
	NONONCOGENIC RETROVIRUS INFECTIONS AS MODELS FOR CHRONIC AND RELAPSING HUMAN DISEASES: A COLLECTION OF PAPERS	
RICHARD T. JOHNSON	Introduction	66
JANICE E. CLEMENTS	Hypothesis on the Molecular Basis of Nononcogenic Retroviral Diseases	68
NEAL NATHANSON, GUDMUNDUR GEORGSSON, PALL A. PÁLSSON, JULIE A. NAJJAR, ROGER LUTLEY, AND GUDMUNDUR PÉTURSSON	Experimental Visna in Icelandic Sheep: The Prototype Lentiviral Infection	75
WILLIAM P. CHEEVERS AND TRAVIS C. MCGUIRE	Equine Infectious Anemia Virus: Immunopathogenesis and Persistence	83
OPENDRA NARAYAN AND LINDA C. CORK	Lentiviral Diseases of Sheep and Goats: Chronic Pneumonia Leukoencephalomyelitis and Arthritis	89
MURRAY B. GARDNER	Retroviral Spongiform Polioencephalomyelopathy	99
	SERIAL FEATURES	
H. M. GILLES	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XVII. Hookworm Infection and Anemia	111
	HISTORICAL ARTICLES	
RICHARD L. HARRIS AND TEMPLE W. WILLIAMS, JR.	"Contribution to the Question of Pneumotyphus": A Discussion of the Original Article by J. Ritter in 1880	119

NOTICES	123
REVIEWERS FOR VOLUME 6	125
STATEMENT OF EDITORIAL POLICY AND INSTRUCTIONS TO AUTHORS	128

*Volume 7 • Number 2 • March-April 1985*

#### REVIEW ARTICLES

L. Å. BURMAN, R. NORRBY, AND B. TROLLFORS	Invasive Pneumococcal Infections: Incidence, Predisposing Factors, and Prognosis	133
MANUEL GARCÍA DE LA TORRE, JOSÉ ROMERO-VIVAS, JESÚS MARTÍNEZ-BELTRÁN, ANTONIO GUERRERO, MARÍA MESEGUER, AND EMILIO BOUZA	Klebsiella Bacteremia: An Analysis of 100 Episodes	143
ORI D. ROTSTEIN, TIMOTHY L. PRUETT, AND RICHARD L. SIMMONS	Mechanisms of Microbial Synergy in Polymicrobial Surgical Infections	151
JESSE E. THOMPSON, JR., SUSAN FORLENZA, AND RAMESH VERMA	Amebic Liver Abscess: A Therapeutic Approach	171
SAMI RAMIA	Transmission of Viral Infections by the Water Route: Implications for Developing Countries	180
W. HENRY BOOM AND CARMELITA TUAZON	Successful Treatment of Multiple Brain Abscesses with Antibiotics Alone	189
RICHARD J. JOHNSON, ELAINE C. JONG, STEVEN B. DUNNING, WILLIAM L. CARBERRY, AND BARBARA H. MINSHAW	Paragonimiasis: Diagnosis and the Use of Praziquantel in Treatment	200
ELIZABETH BARRETT-CONNOR	Is Insulin-Dependent Diabetes Mellitus Caused by Coxsackievirus B Infection? A Review of the Epidemiologic Evidence	207
JUEY-SHIN L. LIN	Human Mycoplasmal Infections: Serologic Observations	216
MARK J. DINUBILE	Therapeutic Role of Granulocyte Transfusions	232
THOMAS BUTLER, JOSEPH KNIGHT, SAMIR K. NATH, PETER SPEELMAN, SWAPAN K. ROY, AND M. A. K. AZAD	Typhoid Fever Complicated by Intestinal Perforation: A Persisting Fatal Disease Requiring Surgical Management	244
ROGER BITAR AND JOHN TARPLEY	Intestinal Perforation in Typhoid Fever: Historical and State-of-the-Art Review	257

#### CASE REPORTS

DAL YOO, WILLIAM H. S. LEE, AND K. J. KWON-CHUNG	Brain Abscesses Due to <i>Pseudallescheria boydii</i> Associated with Primary Non-Hodgkin's Lymphoma of the Central Nervous System: A Case Report and Literature Review	272
---	---	-----

#### SPECIAL ARTICLE

J. ALASTAIR DUDGEON	Presentation of the Galen Medal to John Franklin Enders	278
---------------------	---	-----

ERRATUM (Barriere et al., 1984;6:S812)	284
--	-----

NOTICES	285
---------	-----

INTERNATIONAL SYMPOSIUM ON THE PREVENTION  
OF CONGENITAL RUBELLA INFECTION

	Participants	vi
SAUL KRUGMAN	Preface	S1
SESSION I: DEFINITION OF THE PROBLEM		
LOUIS Z. COOPER	The History and Medical Consequences of Rubella	S2
CATHERINE PECKHAM	Congenital Rubella in the United Kingdom Before 1970: The Prevaccine Era	S11
MADELINE W. APPELL	The Multihandicapped Child with Congenital Rubella: Impact on Family and Community	S17
SESSION II: EPIDEMIOLOGY OF RUBELLA AND CONGENITAL RUBELLA INFECTION		
WALTER A. ORENSTEIN, STEPHEN R. PREBLUD, KENNETH J. BART, AND ALAN R. HINMAN	Methods of Assessing the Impact of Congenital Rubella Infection	S22
F. ASSAAD AND K. LJUNGARS-ESTEVEZ	Rubella—World Impact	S28
MARGARET A. MENSER, JUDY R. HUDSON, ALAN M. MURPHY, AND LAURENCE J. UPFOLD	Epidemiology of Congenital Rubella and Results of Rubella Vac- cination in Australia	S37
T. A. SWARTZ, L. HORNSTEIN, AND I. EPSTEIN	Epidemiology of Rubella and Congenital Rubella Infection in Israel, a Country with a Selective Immunization Program	S42
J. O'H. TOBIN, SHEILA SHEPPARD, R. W. SMITHELLS, ANN MILTON, N. NOAH, AND D. REID	Rubella in the United Kingdom, 1970–1983	S47
HERMANN G. SCHATZMAYR	Aspects of Rubella Infection in Brazil	S53
REISAKU KONO, MUNEHITO HIRAYAMA, CHIEKO SUGISHITA, AND KIKUKO MIYAMURA	Epidemiology of Rubella and Congenital Rubella Infection in Japan	S56
PRADEEP SETH, N. MANJUNATH, AND S. BALAYA	Rubella Infection: The Indian Scene	S64
J. A. A. MINGLE	Frequency of Rubella Antibodies in the Population of Some Tropical African Countries	S68
SU WANNIAN	Rubella in the People's Republic of China	S72
SESSION III: RUBELLA VACCINES		
F. T. PERKINS	Licensed Vaccines	S73
STANLEY A. PLOTKIN AND F. BUSER	History of RA27/3 Vaccine	S77
HAN YARU, ZHAO KAI, GONG YINXIANG, HAO SULAN, WANG SHUZHEN, AND WANG CHANGTAI	Rubella Vaccine in the People's Republic of China	S79
DOROTHY M. HORSTMANN, ANN SCHLUEDERBERG, JEAN E. EMMONS, BRIGITTE K. EVANS, MARTIN F. RANDOLPH, AND WARREN A. ANDIMAN	Persistence of Vaccine-Induced Immune Responses to Rubella: Comparison with Natural Infection	S80

J. E. BANATVALA, JENNIFER M. BEST, SIOBHAN O'SHEA, AND J. A. DUDGEON	Persistence of Rubella Antibodies After Vaccination: Detection After Experimental Challenge	S86
MAX JUST, VRONI JUST, ROSEMARIE BERGER, FELIX BURKHARDT, AND UELI SCHILT	Duration of Immunity After Rubella Vaccination: A Long-Term Study in Switzerland	S91
SANDRA W. BART, HARRISON C. STETLER, STEPHEN R. PREBLUD, NEIL M. WILLIAMS, WALTER A. ORENSTEIN, KENNETH J. BART, ALAN R. HINMAN, AND KENNETH L. HERRMANN	Fetal Risk Associated with Rubella Vaccine: An Update	S95
GISELA ENDERS	Rubella Antibody Titers in Vaccinated and Nonvaccinated Women and Results of Vaccination During Pregnancy	S103
KENNETH L. HERRMANN	SESSION IV: USE OF THE LABORATORY	
GISELA ENDERS	Available Rubella Serologic Tests	S108
ELENA BUIMOVICI-KLEIN AND LOUIS Z. COOPER	Serologic Test Combinations for Safe Detection of Rubella Infections	S113
MARIANNE FORSGREN	Cell-Mediated Immune Response in Rubella Infections	S123
	Standardization of Techniques and Reagents for the Study of Rubella Antibody	S129
	SESSION V: RESEARCH NEEDS	
M. NEAL WAXHAM AND JERRY S. WOLINSKY	A Model of the Structural Organization of Rubella Virions	S133
RALF F. PETTERSSON, CHRISTIAN OKER-BLOM, NISSE KALKKINEN, ANNIKKI KALLIO, ISMO ULMANEN, LEEVI KÄÄRIÄINEN, PAUL PARTANEN, AND ANTTI VAHERI	Molecular and Antigenic Characteristics and Synthesis of Rubella Virus Structural Proteins	S140
PRESTON H. DORSETT, DAVID C. MILLER, KIM Y. GREEN, AND FRANCES I. BYRD	Structure and Function of the Rubella Virus Proteins	S150
GILBERT M. SCHIFF, BETSY C. YOUNG, GERDA M. STEFANOVIC, ERIC F. STAMLER, DOUGLAS R. KNOWLTON, BETTY J. GRUNDY, AND PRESTON H. DORSETT	Challenge with Rubella Virus After Loss of Detectable Vaccine- Induced Antibody	S157
JOHN L. SEVER, MARY ANN SOUTH, AND KATHLEEN A. SHAVER	Delayed Manifestations of Congenital Rubella	S164
FREDDA GINSBERG-FELLNER, MARY E. WITT, BARBARA FEDUN, FLOYD TAUB, MICHAEL J. DOBERSEN, ROBERT C. McEVOY, LOUIS Z. COOPER, ABNER LOUIS NOTKINS, AND PABLO RUBINSTEIN	Diabetes Mellitus and Autoimmunity in Patients with the Congeni- tal Rubella Syndrome	S170
	SESSION VI: IMMUNIZATION STRATEGIES	
KENNETH J. BART, WALTER A. ORENSTEIN, STEPHEN R. PREBLUD, AND ALAN R. HINMAN	Universal Immunization to Interrupt Rubella	S177
J. A. DUDGEON	Selective Immunization: Protection of the Individual	S185



JOHN FURESZ, PAUL VARUGHESE, STANLEY E. ACRES, AND JOHN W. DAVIES	Rubella Immunization Strategies in Canada	S191
E. G. KNOX	Theoretical Aspects of Rubella Vaccination Strategies	S194
JEAN WILSON	Implications of the International Initiative Against Avoidable Disablement ("Impact") for Rubella Control	S198
MARGRÉT GUDNADÓTTIR	Cost-Effectiveness of Different Strategies for Prevention of Congenital Rubella Infection: A Practical Example from Iceland	S200
STEPHEN C. SCHOENBAUM	Benefit-Cost Aspects of Rubella Immunization	S210
ALAN R. HINMAN	Prevention of Congenital Rubella Infection: Symposium Summary	S212

Volume 7 • Number 3 • May-June 1985

#### REVIEW ARTICLES

ANTHONY W. CHOW AND PETER J. JEWESSON	Pharmacokinetics and Safety of Antimicrobial Agents During Pregnancy	287
RICHARD L. HARRIS, VICTOR FAINSTEIN, LINDA ELTING, ROY L. HOPFER, AND GERALD P. BODEY	Bacteremia Caused by <i>Aeromonas</i> Species in Hospitalized Cancer Patients	314
PER KLEMM	Fimbrial Adhesins of <i>Escherichia coli</i>	321
ERIC A. OTTESEN	Efficacy of Diethylcarbamazine in Eradicating Infection with the Lymphatic-Dwelling Filariae of Humans	341
STEPHEN A. BERGER	The Use of Antimicrobial Agents for Noninfectious Diseases	357
SANDRA HANDWERGER AND ALEXANDER TOMASZ	Antibiotic Tolerance Among Clinical Isolates of Bacteria	368

#### THE PHAGOCYtic CELL

MARK E. WILSON, ROBERT J. GENCO, AND RALPH SNYDERMAN	The Phagocytic Cell: Summary	387
RALPH SNYDERMAN	Regulatory Mechanisms of a Chemoattractant Receptor on Human Polymorphonuclear Leukocytes	390
SAMUEL D. WRIGHT	Cellular Strategies in Receptor-Mediated Phagocytosis	395
JOHN K. SPITZNAGEL AND WILLIAM M. SHAFER	Neutrophil Killing of Bacteria by Oxygen-Independent Mechanisms: A Historical Summary	398
MARK E. WILSON	Effects of Bacterial Endotoxins on Neutrophil Function	404
THOMAS E. VAN DYKE	Role of the Neutrophil in Oral Disease: Receptor Deficiency in Leukocytes from Patients with Juvenile Periodontitis	419

#### SERIAL FEATURES

ERIC L. HEWLETT	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XVIII. Pertussis and Diphtheria	426
-----------------	---	-----

#### HISTORICAL ARTICLE

ALFRED S. EVANS	Two Errors in Enteric Epidemiology: The Stories of Austin Flint and Max von Pettenkofer	434
-----------------	---	-----

# CLASSICS IN INFECTIOUS DISEASES

JOHN SNOW	On Continuous Molecular Changes, More Particularly in Their Relation to Epidemic Diseases	441
-----------	---	-----

Volume 7 • Supplement 2 • May-June 1985

## INTERNATIONAL SYMPOSIUM ON YAWS AND OTHER ENDEMIC TREPONEMATOSES

Participants v

CARLYLE GUERRA DE MACEDO AND MARK S. BEAUBIEN	Welcoming Remarks	S217
---	-------------------	------

RICHARD S. SCHWEIKER	Preface	S218
----------------------	---------	------

### SESSION I: DEFINITION OF THE PROBLEM

#### OVERVIEW

G. M. ANTAL AND G. CAUSSE	The Control of Endemic Treponematoses	S220
---------------------------	---------------------------------------	------

#### AFRICA

R. WIDY-WIRSKI	Surveillance and Control of Resurgent Yaws in Africa	S227
V. K. AGADZI, Y. ABOAGYE-ATTA, J. W. NELSON, D. R. HOPKINS, AND P. L. PERINE	Yaws in Ghana	S233

KONAN N'DA	Some Epidemiologic Aspects of Yaws in the Ivory Coast	S237
HAIDAR ABU AHMED MOHAMED	Endemic Treponematoses in the Sudan	S239
ISAK M. TOURÉ	Endemic Treponematoses in Togo and Other West African States	S242

#### ASIA AND THE MIDDLE EAST

ALBERT ZAHRA	Yaws in Southeast Asia: An Overview	S245
EDDY K. C. LO	Yaws in Malaysia	S251
M. SOPHIE REID	Yaws in Papua New Guinea: Extent of the Problem and Status of Control Programs	S254
GEORGE CSONKA AND JOSEPH PACE	Endemic Nonvenereal Trepanematoses (Bejel) in Saudi Arabia	S260

#### THE AMERICAS

RONALD K. ST. JOHN	Yaws in the Americas	S266
P. L. A. NIEMEL, S. SADAL, AND J. J. VAN DER SLUIS	Yaws in Suriname	S273
WILLIAM RODRIGUEZ URIBE	Yaws in Colombia	S276

### SESSION II: STRATEGIES AND TECHNOLOGIES FOR CONTROL

R. R. WILLCOX	Mass Treatment Campaigns Against Endemic Treponematoses	S278
ANDRÉ MEHEUS	Integration of Yaws Control and Primary Health Care	S284
PETER G. JANSSENS	Research: The Prerequisite for Innovative Strategies and Technologies	S289

P. L. PERINE, J. W. NELSON, J. O. LEWIS, S. LISKA, E. F. HUNTER, S. A. LARSEN, V. K. AGADZI, F. KOFI, J. A. K. OFORI, M. R. TAM, AND M. A. LOVETT	New Technologies for Use in the Surveillance and Control of Yaws	S295
--	--	------

### SESSION III: RESEARCH NEEDS

PAUL H. HARDY	Prospects for Improved Laboratory Diagnoses of Treponemal Infections and Species Differentiation	S300
SHEILA A. LUKEHART	Prospects for Development of a Treponemal Vaccine	S305
JACK T. STAPLETON, LOLA V. STAMM, AND PHILIP J. BASSFORD, JR.	Potential for Development of Antibiotic Resistance in Pathogenic Treponemes	S314
STUART T. BROWN	Therapy for Nonvenereal Treponematoses: Review of the Efficacy of Penicillin and Consideration of Alternatives	S318
FERDINAND A. VORST	Clinical Diagnosis and Changing Manifestations of Treponemal Infections	S327
V. K. AGADZI, Y. ABOAGYE-ATTA, J. W. NELSON, D. R. HOPKINS, AND P. L. PERINE	Impact of the Control of Endemic Treponemal Diseases in Ghana on Other Diseases	S332

### SESSION IV: WORLDWIDE CONTROL AND/OR ERADICATION OF YAWS

WILLIAM H. FOEGE	Feasibility of Eradicating Yaws	S335
DONALD R. HOPKINS	Control of Yaws and Other Endemic Treponematoses: Implementation of Vertical and/or Integrated Programs	S338
R. DUNCAN CATTERALL AND JOHN C. HUME	Summary and Recommendations	S343

Volume 7 • Number 4 • July-August 1985

### REVIEW ARTICLES

R. WERK	How Does <i>Toxoplasma gondii</i> Enter Host Cells?	449
CAROL J. BAKER AND DENNIS L. KASPER	Group B Streptococcal Vaccines	458
STEPHAN D. FIHN AND WALTER E. STAMM	Interpretation and Comparison of Treatment Studies for Uncomplicated Urinary Tract Infection in Women	468
IDA M. ONORATO, DAVID M. MORENS, WILLIAM J. MARTONE, AND SALLY K. STANSFIELD	Epidemiology of Cytomegaloviral Infections: Recommendations for Prevention and Control	479
C. R. LIBERTIN, P. E. HERMANS, AND J. A. WASHINGTON II	Beta-Hemolytic Group F Streptococcal Bacteremia: A Study and Review of the Literature	498
CARL E. FRASCH, WENDELL D. ZOLLINGER, AND JAN T. POOLMAN	Serotype Antigens of <i>Neisseria meningitidis</i> and a Proposed Scheme for Designation of Serotypes	504
GEOFFREY J. GORSE AND ROBERT B. BELSHE	Male Genital Tuberculosis: A Review of the Literature with Instructive Case Reports	511

### CASE REPORT

KENNETH V. I. ROLSTON, ROY L. HOPFER, AND DAVID L. LARSON	Infections Caused by <i>Drechslera</i> Species: Case Report and Review of the Literature	525
--	--	-----

# SERIAL FEATURES

DAVID P. STEVENS	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XIX. Giardiasis	530
RICHARD B. HORNICK	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XX. Typhoid Fever	536

# SPECIAL ARTICLES

CALVIN M. KUNIN AND STEPHEN CHAMBERS	Responsibility of the Infectious Disease Community for Optimal Use of Antibiotics: Views of the Membership of the Infectious Diseases Society of America	547
JOHN P. BURKE AND STUART B. LEVY	Summary Report on Worldwide Antibiotic Resistance: International Task Forces on Antibiotic Use	560

# CLASSICS IN INFECTIOUS DISEASES

PAUL B. BEESON, EMMETT S. BRANNON, AND JAMES V. WARREN	Observations on the Sites of Removal of Bacteria from the Blood of Patients with Bacterial Endocarditis	565
PAUL B. BEESON	Retrospective Commentary on the Bacterial Endocarditis Study	574

NOTICES	577
---------	-----

Volume 7 • Supplement 3 • July-August 1985

# IMIPENEM: THE FIRST THIENAMYCIN ANTIBIOTIC

A. M. GEDDES AND W. STILLE	Imipenem: The First Thienamycin Antibiotic	S353
-------------------------------	--	------

# SESSION I. CURRENT PROBLEMS IN HOSPITAL INFECTION

JOHN E. MCGOWAN, JR.	Changing Etiology of Nosocomial Bacteremia and Fungemia and Other Hospital-Acquired Infections	S357
KENNETH H. MAYER AND STEPHEN H. ZINNER	Bacterial Pathogens of Increasing Significance in Hospital-Acquired Infections	S371
LOWELL S. YOUNG	Current Needs in Chemotherapy for Bacterial and Fungal Infections	S380

# SESSION II. ANTIBACTERIAL ACTIVITY OF IMIPENEM

HELMUT KROPP, LYNN GERCKENS, JON G. SUNDELOF, AND FREDERICK M. KAHAN	Antibacterial Activity of Imipenem: The First Thienamycin Antibiotic	S389
J. D. WILLIAMS	Activity of Imipenem Against <i>Pseudomonas</i> and <i>Bacteroides</i> Species	S411
HANNAH M. WEXLER AND SYDNEY M. FINEGOLD	In Vitro Activity of Imipenem Against Anaerobic Bacteria	S417
CHRISTOPH W. C. WEIMER, BRITTA KUBENS, AND WOLFGANG OFFERKUCH	Influence of Imipenem on the Serum Resistance of Enterobacteriaceae	S426
C. E. NORD, L. KAGER, A. PHILIPSON, AND G. STIERNSTEDT	Effect of Imipenem/Cilastatin on the Colonic Microflora	S432

### SESSION III: PHARMACOKINETICS OF IMIPENEM/CILASTATIN

- |   |   |      |
|---|---|------|
| J. D. ROGERS, M. A. P. MEISINGER,<br>F. FERBER, G. B. CALANDRA,<br>J. L. DEMETRIADES, AND J. A. BLAND<br>S. RAGNAR NORRBY | Pharmacokinetics of Imipenem and Cilastatin in Volunteers | S435 |
|   | Imipenem/Cilastatin: Rationale for a Fixed Combination    | S447 |

### SESSION IV: CLINICAL EFFICACY AND SAFETY OF IMIPENEM/CILASTATIN

- |  |  |                                      |
|--|--|--------------------------------------|
| F. DIAZ-MITOMA, G. K. M. HARDING<br>T. J. LOUIE, M. THOMSON, M. JAMES,<br>AND A. R. RONALD<br>DANIEL STAMBOULIAN,<br>EDUARDO A. ARGÜELLO, ABEL JASOVICH,<br>OSCAR VILLAR, AND FRANCISCO MAGLIO<br>JORGE G. GUERRA, ERNESTO CASALINO,<br>JUAN C. PALOMINO, EDUARDO BARBOZA,<br>MARIO DEL CASTILLO,<br>MANUEL GONZALEZ DEL RIEGO,<br>VICTOR HUAPAYA, AND<br>ELEAZAR ANTÚNEZ DE MAYOLO<br>PRAMOD M. SHAH  | Prospective Randomized Comparison of Imipenem/Cilastatin and Cefotaxime for Treatment of Lung, Soft Tissue, and Renal Infections<br>Comparative Clinical Evaluation of Imipenem/Cilastatin vs. Cefotaxime in Treatment of Severe Bacterial Infections<br>Imipenem/Cilastatin vs. Gentamicin/Clindamycin for the Treatment of Moderate to Severe Infections in Hospitalized Patients<br>Clinical Experience with Imipenem/Cilastatin: Analysis of a Multicenter Study | S452<br>S458<br>S463<br>S471         |
| DAVID TRUMBORE, RAYMOND PONTZER,<br>MATTHEW E. LEVISON, DONALD KAYE,<br>MICHAEL CYNAMON, CHIEN LIU,<br>DANIEL R. HINTHORN, JAMES S. TAN,<br>AND THOMAS M. FILE<br>L. R. KRILOV, J. L. BLUMER,<br>R. C. STERN, A. I. HARTSTEIN,<br>B. N. IGLEWSKI, AND D. A. GOLDMANN<br>P. L. CHIODINI, A. M. GEDDES,<br>E. G. SMITH, C. P. CONLON, AND<br>I. D. FARRELL<br>ROBERT G. BROOKS, ROBERT E. MCCABE,<br>KENNETH L. VOSTI, AND JACK S.<br>REMINGTON<br>DONALD M. NIELSEN, JAMES R. KATZ,<br>RONALD D. AHLLOY, RALPH S. HANSEN,<br>AND RICHARD D. MEYER | Multicenter Study of the Clinical Efficacy of Imipenem/Cilastatin for Treatment of Serious Infections<br>Imipenem/Cilastatin in Acute Pulmonary Exacerbations of Cystic Fibrosis<br>Imipenem/Cilastatin in the Treatment of Serious Bacterial Infections<br>Open Trial of Imipenem/Cilastatin for Serious Bacterial Infections<br>Imipenem/Cilastatin Therapy for Serious Bacterial Infections   | S476<br>S482<br>S490<br>S496<br>S506 |

### SESSION V: REVIEWS OF CLINICAL EXPERIENCE WITH IMIPENEM/CILASTATIN

- |                         |  |      |
|-------------------------|--|------|
| J. F. ACAR              | Therapy for Lower Respiratory Tract Infections with Imipenem/Cilastatin: A Review of Worldwide Experience      | S513 |
| L. KAGER AND C. E. NORD | Imipenem/Cilastatin in the Treatment of Intraabdominal Infections: A Review of Worldwide Experience            | S518 |
| RICHARD L. SWEET        | Imipenem/Cilastatin in the Treatment of Obstetric and Gynecologic Infections: A Review of Worldwide Experience | S522 |



CYNTHIA WANG, GARY B. CALANDRA,  
MOHAMMED A. AZIZ, AND  
KENNETH R. BROWN

Efficacy and Safety of Imipenem/Cilastatin: A Review of World-  
wide Clinical Experience

S528

Volume 7 • Number 5 • September-October 1985

# REVIEW ARTICLES

BERNARD J. BRABIN	Epidemiology of Infection in Pregnancy	579
I. W. FONG AND K. B. TOMKINS	Review of <i>Pseudomonas aeruginosa</i> Meningitis with Special Emphasis on Treatment with Ceftazidime	604
PETER A. GROSS, A. LAWRENCE GOULD, AND ARTHUR E. BROWN	Effect of Cancer Chemotherapy on the Immune Response to Influenza Virus Vaccine: Review of Published Studies	613
WALTER M. HOLLERAN, JORDAN R. WILBUR, AND MICHAEL W. DE GREGORIO	Empiric Amphotericin B Therapy in Patients with Acute Leukemia	619
MICHAEL SANDS, MICHAEL A. KRON, AND RICHARD B. BROWN	Pentamidine: A Review	625
B. FONT-CREUS, F. BELLA-CUETO, E. ESPEJO-ARENAS, R. VIDAL-SANAHUJA, T. MUNOZ-ESPIN, M. NOLLA-SALAS, A. CASAGRAN-BORRELL, J. MERCADE-CUESTA, AND F. SEGURA-PORTA	Mediterranean Spotted Fever: A Cooperative Study of 227 Cases	635
JACK D. MCCUE, CHARLES HANSEN, AND PETER GAL	Hospital Charges for Antibiotics	643
RUTH HORN, BRIAN WONG, TIMOTHY E. KIEHN, AND DONALD ARMSTRONG	Fungemia in a Cancer Hospital: Changing Frequency, Earlier Onset, and Results of Therapy	646
J. ARIZA, F. GUDIOL, J. M. VALVERDE, R. PALLARES, P. FERNANDEZ-VILADRICH, G. RUI, L. ESPADALER, AND F. FERNANDEZ-NOGUES	Brucellar Spondylitis: A Detailed Analysis Based on Current Findings	656
DENNIS KUNIMOTO AND ROBERT C. BRUNHAM	Human Immune Response and <i>Chlamydia trachomatis</i> Infection	665
	SERIAL FEATURES	
STEPHEN BERMAN AND KENNETH MCINTOSH	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXI. Acute Respiratory Infections	674
	SPECIAL ARTICLE	
LOUIS WEINSTEIN	Clinically Benign Fever of Unknown Origin: A Personal Retro- spective	692
	INTERNATIONAL NOTES	
M. MONTEJO BARANDA, J. CORRAL CARRANCEJA, AND C. AGUIRRE ERRASTI	Q Fever in the Basque Country: 1981-1984	700

	HISTORICAL ARTICLE	
THOMAS H. JUKES	Some Historical Notes on Chlortetracycline	702
	CORRESPONDENCE	
PETER EBBESEN AND MAD S MELBYE	Recommendations for an International Health Organization in Handling a Future AIDS-Like Epidemic	708
	NOTICES	710
	ERRATUM (7 [Suppl 1]; S113-22)	710
	Volume 7 • Number 6 • November-December 1985	
	INFECTIOUS CAUSES OF BLINDNESS	
	I. TRACHOMA	
HUGH R. TAYLOR	Review of Trachoma: An Introduction	711
JULIUS SCHACHTER	Overview of <i>Chlamydia trachomatis</i> Infection and the Requirements for a Vaccine	713
J. THOMAS GRAYSTON, SAN-PIN WANG, LUNG-JUI YEH, AND CHO-CHOU KUO	Importance of Reinfection in the Pathogenesis of Trachoma	717
S. DAROUGAR	The Humoral Immune Response to Chlamydial Infection in Humans	726
A. BRUCE MACDONALD	Antigens of <i>Chlamydia trachomatis</i>	731
HUGH R. TAYLOR	Ocular Models of Chlamydial Infection	737
ALAN P. JOHNSON	Pathogenesis and Immunology of Chlamydial Infections of the Genital Tract	741
DOROTHY L. PATTON	Immunopathology and Histopathology of Experimental Chlamydial Salpingitis	746
DWIGHT M. WILLIAMS AND JULIUS SCHACHTER	Role of Cell-Mediated Immunity in Chlamydial Infection: Implications for Ocular Immunity	754
JOHN D. TREHARNE	The Community Epidemiology of Trachoma	760
HUGH R. TAYLOR AND ALFRED SOMMER	Risk-Factor Studies as an Epidemiologic Tool	765
CHANDLER R. DAWSON AND JULIUS SCHACHTER	Strategies for Treatment and Control of Blinding Trachoma: Cost-Effectiveness of Topical or Systemic Antibiotics	768
B. THYLEFORS	Development of Trachoma Control Programs and the Involvement of National Resources	774
FRED C. HOLLOWES	Community-Based Action for the Control of Trachoma	777
FREDERICK L. DUNN	Sociomedical Contributions to Trachoma Research and Intervention	783
	II. ONCHOCERCIASIS	
HUGH R. TAYLOR	Review of the Immunologic Aspects of Onchocerciasis: An Introduction	787
BRUCE M. GREENE, AIAH A. GBKIMA, EBERHARD J. ALBIEZ, AND HUGH R. TAYLOR	Humoral and Cellular Immune Responses to <i>Onchocerca volvulus</i> Infection in Humans	789

ERIC A. OTTESEN	Immediate Hypersensitivity Responses in the Immunopathogenesis of Human Onchocerciasis	796
C. D. MACKENZIE, J. F. WILLIAMS, B. M. SISLEY, M. W. STEWARD, AND J. O'DAY	Variations in Host Responses and the Pathogenesis of Human Onchocerciasis	802
DANIEL H. CONNOR, GLADYS H. GEORGE, AND DEAN W. GIBSON	Pathologic Changes of Human Onchocerciasis: Implications for Future Research	809
JOHN J. DONNELLY, JOHN H. ROCKEY, HUGH R. TAYLOR, AND E. J. L. SOULSBY	Onchocerciasis: Experimental Models of Ocular Disease	820
NIKLAUS WEISS	Monoclonal Antibodies as Investigative Tools in Onchocerciasis	826
J. F. WILLIAMS, MOHAMED EL KHALIFA, C. D. MACKENZIE, AND B. SISLEY	Antigens of <i>Onchocerca volvulus</i>	831
ROBERT G. HAMILTON	Application of Immunoassay Methods in the Serodiagnosis of Human Filariasis	837
HUGH R. TAYLOR	Global Priorities in the Control of Onchocerciasis	844
	NOTICES	847
	ERRATUM (Wang C, Calandra GB, Aziz MA, and Brown KR, 7[Suppl 3]:S528-36)	847
	INDEXES TO VOLUME 7	
	Author Index	849
	Subject Index	852
	Contents for Volume 7	iii

Volume 7 • Supplement 4 • November-December 1985

#### GRAM-NEGATIVE AEROBIC BACTERIAL INFECTIONS: A FOCUS ON DIRECTED THERAPY, WITH SPECIAL REFERENCE TO AZTREONAM

HAROLD C. NEU	Introduction to the Symposium	S537
	SESSION I: REVIEW OF THE PROBLEM	
LOUIS WEINSTEIN	Gram-Negative Bacterial Infections: A Look at the Past, a View of the Present, and a Glance at the Future	S538
JACQUES F. ACAR	Problems and Changing Patterns of Resistance with Gram-Negative Bacteria	S545
J. KLASTERSKY	Nosocomial Infections Due to Gram-Negative Bacilli in Compromised Hosts: Considerations for Prevention and Therapy	S552
J. DAVIS ALLAN AND ROBERT C. MOELLERING, JR.	Management of Infections Caused by Gram-Negative Bacilli: The Role of Antimicrobial Combinations	S559
LOWELL S. YOUNG	Treatment of Infections Due to Gram-Negative Bacilli: A Perspective of Past, Present, and Future	S572
	SESSION II: DISCOVERY, DEVELOPMENT, AND PROPERTIES OF AZTREONAM	
R. B. SYKES AND D. P. BONNER	Discovery and Development of the Monobactams	S579

ARTHUR L. BARRY, CLYDE THORNSBERRY, RONALD N. JONES, AND THOMAS L. GAVAN	Aztreonam: Antibacterial Activity, $\beta$ -Lactamase Stability, and Interpretive Standards and Quality Control Guidelines for Disk-Diffusion Susceptibility Tests	S594
EDWARD A. SWABB	Clinical Pharmacology of Aztreonam in Healthy Recipients and Patients: A Review	S605
N. FRANKLIN ADKINSON, JR., ANDREW SAXON, MICHAEL R. SPENCE, AND EDWARD A. SWABB	Cross-Allergenicity and Immunogenicity of Aztreonam	S613
FRED R. SATTler, MARGARET SCHRAMM, AND EDWARD A. SWABB	Safety of Aztreonam and SQ 26,992 in Elderly Patients with Renal Insufficiency	S622
D. VAN DER WAAIJ	Selective Decontamination of the Digestive Tract with Oral Aztreonam and Temocillin	S628
W. MICHAEL SCHELD, JAMES P. BRODEUR, PAMELA A. FORESMAN, JEAN C. GRATZ, AND GEORGE T. RODEHEAVER	Comparative Evaluation of Aztreonam for Experimental Bacterial Meningitis and Cerebritis	S635
THOMAS J. NEWMAN, GERALD R. DRESLINSKI, AND SAMIR S. TADROS	Safety Profile of Aztreonam in Clinical Trials	S648
	SESSION III: LOWER RESPIRATORY TRACT INFECTIONS	
MATTHEW E. LEVISON AND DONALD KAYE	Pneumonia Caused by Gram-Negative Bacilli: An Overview	S656
T. M. NOLEN, H. L. PHILLIPS, AND H. J. HALL	Comparison of Aztreonam and Tobramycin in the Treatment of Lower Respiratory Tract Infections Caused by Gram-Negative Bacilli	S666
BRIAN E. SCULLY, CELIA N. ORES, ALICE S. PRINCE, AND HAROLD C. NEU	Treatment of Lower Respiratory Tract Infections Due to <i>Pseudomonas aeruginosa</i> in Patients with Cystic Fibrosis	S669
EDWARD A. SWABB, CAROLYN O. CONE, AND J. GORDON MUIR	Summary of Worldwide Clinical Trials of Aztreonam in Patients with Lower Respiratory Tract Infections	S675
	SESSION IV: OBSTETRIC AND GYNECOLOGIC INFECTION	
WILLIAM J. LEDGER	Current Problems in Antibiotic Treatment in Obstetrics and Gynecology	S679
RONALD S. GIBBS, JORGE D. BLANCO, AND STEVEN BERNSTEIN	Role of Aerobic Gram-Negative Bacilli in Endometritis After Cesarean Section	S690
MELVIN G. DODSON AND SEBASTIAN FARO	The Polymicrobial Etiology of Acute Pelvic Inflammatory Disease and Treatment Regimens	S696
SHARON A. HENRY	Overall Clinical Experience with Aztreonam in the Treatment of Obstetric-Gynecologic Infections	S703
	SESSION V: INTRAABDOMINAL INFECTIONS	
RONALD LEE NICHOLS	Intraabdominal Infections: An Overview	S709
NANCY E. WINSLADE, IAN L. SMITH, GARY W. SIMONS, DOUGLAS J. SWANSON, ALESSANDRA VIGANO, PHILIP B. WELS, AND JEROME J. SCHENTAG	Pharmacokinetics and Extravascular Penetration of Aztreonam in Patients with Abdominal Sepsis	S716
DARIO BIROLINI, MARCUS F. MORAES, AND OLAVO SOARES DE SOUZA	Aztreonam plus Clindamycin vs. Tobramycin plus Clindamycin for the Treatment of Intraabdominal Infections	S724
SHARON A. HENRY	Overall Clinical Experience with Aztreonam in the Treatment of Intraabdominal Infections	S729

<b>SESSION VI: INFECTIONS IN THE NEUTROPENIC PATIENT</b>	
STEPHEN C. SCHIMPF	Overview of Empiric Antibiotic Therapy for the Febrile Neutropenic Patient S734
PAULA JONES, KENNETH ROLSTON, VICTOR FAINSTEIN, LINDA ELTING, AND GERALD P. BODEY	Aztreonam plus Vancomycin (plus Amikacin) vs. Moxalactam plus Ticarcillin for the Empiric Treatment of Febrile Episodes in Neu- tropic Cancer Patients S741
THOMAS J. LOUIE, HILARY CHUBB, ERIC J. BOW, JOHN M. CONLY, GODFREY K. M. HARDING, ELEANOR RAYNER, AND MARIKO JAMES	Preservation of Colonization Resistance Parameters During Empiric Therapy with Aztreonam in the Febrile Neutropenic Patient S747
<b>SESSION VII: URINARY TRACT INFECTIONS</b>	
EDWARD H. KASS	Bacteriuria and Excess Mortality: What Should the Next Steps Be? S762
CLAIR E. COX	Aztreonam Therapy for Complicated Urinary Tract Infections Caused by Multidrug-Resistant Bacteria S767
EDWARD A. SWABB, STEPHEN A. JENKINS, AND J. GORDON MUIR	Summary of Worldwide Clinical Trials of Aztreonam in Patients with Urinary Tract Infections S772
<b>SESSION VIII: OTHER GRAM-NEGATIVE INFECTIONS</b>	
HAROLD C. NEU	Infections Due to Gram-Negative Bacteria: An Overview S778
WILLIAM J. SIMONS AND TERRENCE J. LEE	Aztreonam in the Treatment of Bone and Joint Infections Caused by Gram-Negative Bacilli S783
BRIAN E. SCULLY AND SHARON A. HENRY	Clinical Experience with Aztreonam in the Treatment of Gram-Nega- tive Bacteremia S789
LAWRENCE A. CONE AND DAVID R. WOODARD	Aztreonam Therapy for Serious Gram-Negative Bacillary Infections S794
PETER P. MCKELLAR	Clinical Evaluation of Aztreonam Therapy for Serious Infections Due to Gram-Negative Bacteria S803
<b>SESSION IX: SUMMARY OF CLINICAL EXPERIENCE WITH AZTREONAM</b>	
KOHEI HARA, HIROYUKI KOBAYASHI, TSUNEO NISHIURA, JIRO YURA, AND ATSUSHI SAITO	Clinical Studies of Aztreonam in Japan S810
W. STILLE AND J. GILLISSEN	Clinical Experience with Aztreonam in Germany and Austria S825
GEORGE K. DAIKOS	Clinical Experience with Aztreonam in Four Mediterranean Countries S831
S. RAGNAR NORRBY	Clinical Experience with Aztreonam in Europe: A Summary of Studies in Belgium, England, Finland, Ireland, The Netherlands, Portugal, and Sweden S836
HAROLD C. NEU	Concluding Statement S840



